GlaxoSmithKline: Rhinitis, Allergic, Perennial trials

The registry lists 28 Rhinitis, Allergic, Perennial studies with GlaxoSmithKline as lead sponsor. 0 are open to participants now and 13 have results posted.

Phase 1 1Phase 2 1Phase 3 16Phase 4 7No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Study FFR116364, a Placebo-controlled Study of GW685698X in Paediatric Subjects With Perennial Allergic RhinitisCompletedNCT01630135Phase 3Results posted
• A Phase-IV, Open-label Study to Evaluate Safety/Tolerability of Once-daily AVAMYS (TM) Aqueous Nasal Spray 110mcg Among Vietnamese Adult Patients With Established Perennial Allergic RhinitisCompletedNCT01270958Phase 4Results posted
• A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Fluticasone Furoate Nasal Spray for 2 Weeks in Chinese Adult and Adolescent Subjects With Allergic RhinitisCompletedNCT01231464Phase 3Results posted
• A Randomised, Double Blind, Placebo Controlled, 4 Period, Incomplete Block, Crossover Study Assessing the Dose-response Curve of Fluticasone Propionate in an Antigen Challenge ChamberCompletedNCT00848965Phase 4Results posted
• A Pilot Study In Adults And Adolescents With Irritant (Non-Allergic) RhinitisCompletedNCT00730756Phase 2Results posted
• A Clinical Study With Fluticasone Furoate Nasal Spray And Vehicle Placebo For The Treatment Of Perennial (Year-round) Allergic RhinitisCompletedNCT00682643Phase 4Results posted
• A Clinical Study To Test A Nasal Spray (Fluticasone Furoate Nasal Spray) For The Treatment Of Perennial (Year-round) Allergic RhinitisCompletedNCT00609674Phase 4Results posted
• Phase 4 Fluticasone Furoate Nasal Spray (VERAMYST) Long Term Pediatric Growth Study.CompletedNCT00570492Phase 4Results posted
• Comparator Study Evaluating Patient Preference Of FFNS vs. FPNSCompletedNCT00539006Phase 4Results posted
• Comparator Study Evaluating Patient Experience And Preference Of FFNS vs. FPNSCompletedNCT00519636Phase 4Results posted
• Fluticasone Nasal Spray Patient Preference StudyCompletedNCT00398476Phase 3Results posted
• Validation Of Preference Module Of Experience With Allergic Rhinitis Nasal Sprays Questionnaire (EARNS-Q)CompletedNCT00346775Phase 3Results posted
• Once-Daily Investigational Nasal Spray In Adults And Adolescents With Perennial Allergic Rhinitis (PAR)CompletedNCT00289198Phase 3Results posted
• A Comparison of Patients on AVAMYS ® Versus NASONEX (A Trade Mark of Schering Corporation) and FLIXONASE ® on Key Health Outcome MeasuresCompletedNCT01199757
• Flixonase Safety in Patients With Allergic Rhinitis (AR)CompletedNCT01077609
• Regulatory AVAMYS Nasal Spray PMSCompletedNCT01001130
• Cetirizine Placebo Controlled Study For Perennial Allergic RhinitisCompletedNCT00490204Phase 3
• Effects Of Single Doses Of GW784568X On Allergic Rhinitis Symptoms In Male Subjects Whilst In An Environmental ChamberCompletedNCT00404586Phase 1
• Study Of Perennial Allergic RhinitisCompletedNCT00358475Phase 3
• Perennial Allergic Rhinitis In Pediatric SubjectsCompletedNCT00257595Phase 3
• Study Of Perennial Allergic Rhinitis In PediatricsCompletedNCT00253058Phase 3
• Long Term Safety Of GW685698X Via Nasal BiopsyCompletedNCT00224523Phase 3
• A Study Of GW685698X For The Treatment Of Perennial Allergic Rhinitis In PediatricsCompletedNCT00116883Phase 3
• A Study of GW685698X for the Treatment Of Perennial Allergic Rhinitis in Adolescents and AdultsCompletedNCT00116818Phase 3
• Safety Study To Assess Growth In Children With Seasonal Allergic And/Or Perennial Allergic Rhinitis Treated With GW685698X Aqueous Nasal Spray Or Placebo Nasal SprayCompletedNCT00109486Phase 3
• Perennial Allergic Rhinitis Study In Pediatric SubjectsCompletedNCT00108914Phase 3
• Seasonal Allergic Rhinitis In Pediatric SubjectsCompletedNCT00107757Phase 3
• A Study To Evaluate The Efficacy And Safety Of A Once-Daily Investigational Nasal Spray In Adults And Adolescents With Perennial Allergic Rhinitis (PAR).CompletedNCT00103454Phase 3